Clinical trial
Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic…
NCT00285376 · Genaissance Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00285376 |
|---|---|
| Title | Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response |
| Official title | A Randomized, Double-Blind, Placebo Controlled Study Assessing the Efficacy and Safety of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder |
| Lead sponsor | Genaissance Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Depressive Disorder, Major |
| Intervention type | Drug |
| Interventions | vilazodone |
| Enrollment | 410 |
| Start date | Feb 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Feb 2, 2006 |
| Last update posted | Feb 21, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: